With 0.62 million shares changed hands, the volume of the stock remained lighter than its average volume of 13.15 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4399 whereas the lowest price it dropped to was $0.401. The 52-week range on KZIA shows that it touched its highest point at $1.58 and its lowest point at $0.19 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at 2.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KZIA was up-trending over the past week, with a rise of 32.09%, but this was up by 1.82% over a month. Three-month performance surged to 101.12% while six-month performance rose 30.88%. The stock lost -56.94% in the past year, while it has lost -1.93% so far this year.
Float and Shares Shorts:
At present, 23.63 million KZIA shares are outstanding with a float of 23.62 million shares on hand for trading. On 2024-09-13, short shares totaled 1.6 million, which was 482.0 higher than short shares on 1723680000. In addition to Dr. John Edwin Friend II, M.D. as the firm’s CEO, MD & Director, Ms. Gabrielle Heaton BBUS (ACC), CPA serves as its Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer.
Institutional Ownership:
Through their ownership of 0.01364 of KZIA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. EBITDA for the full year was -$22.79M.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KZIA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.